Intercept Pharmaceuticals Concludes Public Trading Chapter

The publicly traded journey of Intercept Pharmaceuticals has reached its conclusion. Following its complete acquisition by Italian pharmaceutical company Alfasigma S.p.A., the biotechnology firm’s shares are no longer available on public exchanges. Financial data platforms now classify the stock as an inactive instrument, confirming that public market activity has ceased entirely.

On November 8, 2023, Alfasigma executed the final phase of its takeover strategy, acquiring Intercept Pharmaceuticals in full. The transaction involved a cash payment of $19 per share, amounting to a total deal value of approximately $794 million. From that date forward, Intercept began operating as a wholly-owned subsidiary of Alfasigma, marking the end of its independent presence on public markets.

Market Exit Completes Corporate Evolution

The acquisition... Read more...